Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-07-25
2006-07-25
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C536S023100, C536S023500, C530S350000
Reexamination Certificate
active
07081345
ABSTRACT:
The invention concerns the use of at least one polypeptide comprising a protein fragment to obtain a diagnostic, prognostic, prophylactic or therapeutic composition for detecting, preventing or treating a pathological condition associated with a degenerative and/or neurological and/or autoimmune disease, said protein being selected among the proteins whereof the peptide sequence in native state corresponds to SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14, SEQ ID No 15, SEQ ID No 16, SEQ ID No 17, SEQ ID No 18, SEQ ID No 19, SEQ ID No 20, SEQ ID No 21, SEQ ID No 22, SEQ ID No 23, SEQ ID No 24, SEQ ID No 25, SEQ ID No 26, SEQ ID No 27, SEQ ID No 28, and SEQ ID No 29, and the peptide sequences having at least 70% identity, preferably at least 80% identity and advantageously at least 98% identity with any one of the peptide sequences SEQ ID No 1 to SEQ ID No 8 and SEQ ID No 10 to SEQ ID No 29, and the peptide sequences or fragments of said sequences belonging to a common family of proteins selected among perlecan, the precursor of the retinol-binding plasmatic protein, of the GM2 activator protein, of calgranulin B and of saponin B.
REFERENCES:
patent: 5876954 (1999-03-01), Perron et al.
patent: 2214843 (1999-04-01), None
patent: A 8-308582 (1996-11-01), None
patent: WO 90/07712 (1990-07-01), None
patent: WO 97/33466 (1997-09-01), None
patent: WO 98/11439 (1998-03-01), None
Xie et al, Biochem. Biophys. Res. Comm. 177: 1217 (1991).
Nagarajan et al, Biochem. J. 282: 807 (1992).
Li et al, J. Biol. Chem. 270: 24246 (1995).
Rieger et al., “Un facteur gliotoxique et 1a sclerose en plaques”, C.R. Acad. Sci. Paris, Sciences de la vie/Life sciences, XP 000602023, pp. 343-350, 1996.
Kisilevsky et al., “Arresting amyloidosisin vivousing small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease”, Nature Medicine, vol. 1, No. 2, pp. 143-148, 1995.
Conzelmann et al., “Purification and Characterization of an Activator Protein for the Degradation of Glycolipis GM2and GA2by Hexosaminidase A”, Hoppe-Seyler's Z. Physiol. Chem., pp. 1837-1849, 1979, vol. 360.
Hitomi et al., “A novel calcium-binding protein in amniotic fluid, CAAF1: its molecular cloning and tissue distribution”, Journal of Cell Science, pp. 805-815, 1996, vol. 109.
Raftery et al., “Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding”, Biochem J., pp. 285-293, 1996, vol. 316.
Kase et al., “Only sphingolipid activator protein B (SAP-B or saposin B) stimulates the degradation of globotriaosylceramide by recombinant human lysosomal α-galactosidase in a detergent-free liposomal system”, FEBS Letters, pp. 74-76, 1996, vol. 393.
Bierfreund et al., “Recombinant GM2-Activator Protein Stimulates in Vivo Degradation of GA2 in GM2 Gangliosidosis AB Variant Fibroblasts But Exhibits No Detectable Binding of GA2 in an In Vitro Assay”, Neurochemical Research, vol. 24, No. 2, pp. 295-300, 1999.
Longbottom et al., “Subunit structure of calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial cells”, Biochimica et Biophysica Acta, pp. 215-222, 1992, vol. 1120.
Raftery et al., “Overexpression, Oxidative Refolding, and Zinc Binding of Recombinant Forms of the Murine S100 Protein MRP14 (S100A9)”, Protein Expression and Purification, pp. 228-235, 1999, vol. 15.
Klempt et al., “The heterodimer of the Ca2+-binding proteins MRP8 and MRP14 binds arachidonic acid”, FEBS Letters, pp. 81-84, 1997, vol. 408.
Katz et al., “Colorimetric diagnosis of prolonged bluetongue viremia in sheep, using an enzyme-linked oligonucleotide sorbent assay of amplified viral nucleic acids”, Am J Vet Res, vol. 54, No. 12, pp. 2021-2026, 1993.
Toes et al., “Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encloding multiple tumor-associated cytotoxic T lumphocyte epitopes in a string-of-beads fashion”, Proc. Natl. Acad. Sci., vol. 94, pp. 14660-14665, 1997.
Bird et al., “Single-Chain Antigen-Binding Proteins”, Science Reports, pp. 423-426, 1988, vol. 242.
Arakawa et al., “Cloning and Sequencing of the VHand VκGenes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody”, J. Biochem, pp. 657-662, vol. 120, No. 3, 1996.
Chaudhary et al., “A recombinant immunotoxin consisting of two antibody variable domains fused toPseudomonasexotoxin”, Letters to Nature, vol. 339, pp. 394-397, 1989.
Behr et al., “Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA”, Proc. Natl. Acad. Sci, vol. 86, pp. 6982-6986, 1989.
Debrick et al., “Macrophages As Accessory Cells For Class I MHC-Restricted Immune Responses”, The Journal of Immunology, vol. 147, No. 9, pp. 2846-2851, 1991.
Kovacsovics-Bankowski et al., “A Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules”, Science Reports, vol. 267, pp. 243-246, 1995.
Kovacsovics-Bankowski et al., “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages”, Proc. Natl. Acad. Sci, vol. 90, pp. 4942-4946, 1993.
Racoosin et al., “M-CSF-induced macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages”, Journal of Cell Science, pp. 867-880, 1992, vol. 102.
Finke et al. “Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene”, Gene Therapy, pp. 31-39, 1998, vol. 5.
Haensler et al., “Polyamidoamine Cascade Polymers Mediate Efficient Transfection of Cells in Culture”, Bioconjugate Chem., pp. 372-379, 1993, vol. 4.
Deo et al., “Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies”, Immunology Today, vol. 18, pp. 127-135, 1997.
Pession et al., “Molecular Cloning of NKp46: A Novel Member of the Immunoglobulin Superfamily Involved in Triggering of Natural Cytotoxicity”, J. Exp. Med, vol. 188, No. 5, pp. 953-960, 1998.
Kawano et al., “Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells”, Proc. Natl. Acad. Sci., vol. 95, pp. 5690-5693, 1998.
McCoy et al., “Pulmonary Inflammation Induced by Incomplete or Inactivated Adenoviral Particles”, Human Gene Therapy, pp. 1553-1560, 1995, vol. 6.
Cotten et al., “Non-viral approaches to gene therapy”, Current Biology, pp. 705-710, 1993.
Felgner et al., “Cationic liposome-mediated transfection”, Nature, vol. 337, pp. 387-388, 1989.
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure”, Proc. Natl. Acad. Sci, vol. 84, pp. 7413-7417, 1987.
Felgner et al., “Cationic Lipid-Mediated Delivery of Polynucleotides”, Methods, pp. 67-75, 1993, vol. 5.
Gao et al., “A Novel Cationic Liposome Reagent For Efficient Transfection of Mammalian Cells”, Biochemical and Biophysical Research Communication, vol. 179, No. 1, pp. 280-285, 1991.
Groettrup et al., “Peptide antigen production by the proteasome: complexity provides efficiency”, Immunology Today, vol. 17, No. 9, pp. 429-435, 1996.
Polydefkis et al., “Achor Sequence-Dependent Endogenous Processing of Human Immunodeficiency Virus 1 Envlope Glycoprotein gp160 For CD4+ T Cell Recognition”, J. Exp Med, vol. 171, pp. 875-887, 1990.
Sallusto et al., “Dendritic Cells Use Macropinocytosis and the Mannose
Charles Marie-Helene
Kolbe Hanno
Malcus Carine
Perron Herve
Roecklin Dominique
Biomerieux Stelhys
Martinell James
LandOfFree
Use of a polypeptide for detecting, preventing or treating a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a polypeptide for detecting, preventing or treating a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a polypeptide for detecting, preventing or treating a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549511